| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $105,250 | 13 | 100 |
| Bertrand William C JR | Chief Operating Officer | 0 | $0 | 3 | $14,604 | $-14,604 |
| Lunger John | Chief Patient Supply Officer | 0 | $0 | 3 | $14,604 | $-14,604 |
| Norry Elliot | Chief Medical Officer | 0 | $0 | 3 | $16,163 | $-16,163 |
| Piccina Cintia | Chief Commercial Officer | 0 | $0 | 2 | $30,281 | $-30,281 |
| Rawcliffe Adrian | Chief Executive Officer | 0 | $0 | 3 | $52,413 | $-52,413 |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Over the last 12 months, insiders at Adaptimmune Therapeutics plc have bought $0 and sold $105,250 worth of Adaptimmune Therapeutics plc stock.
On average, over the past 5 years, insiders at Adaptimmune Therapeutics plc have bought $117,557 and sold $573,911 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 39,000 shares for transaction amount of $11,326 was made by Wood Gavin (Chief Financial Officer) on 2022‑05‑20.
| 2025-01-17 | Sale | Rawcliffe Adrian | Chief Executive Officer | 30,601 0.0121% | $0.58 | $17,773 | -49.89% | |
| 2025-01-17 | Sale | Norry Elliot | Chief Medical Officer | 5,584 0.0022% | $0.58 | $3,243 | -49.89% | |
| 2025-01-17 | Sale | Lunger John | Chief Patient Supply Officer | 5,584 0.0022% | $0.58 | $3,243 | -49.89% | |
| 2025-01-17 | Sale | Bertrand William C JR | Chief Operating Officer | 5,584 0.0022% | $0.58 | $3,243 | -49.89% | |
| 2025-01-15 | Sale | Rawcliffe Adrian | Chief Executive Officer | 29,096 0.0107% | $0.57 | $16,724 | -51.88% | |
| 2025-01-15 | Sale | Piccina Cintia | Chief Commercial Officer | 12,991 0.0048% | $0.57 | $7,467 | -51.88% | |
| 2025-01-15 | Sale | Norry Elliot | Chief Medical Officer | 9,803 0.0036% | $0.57 | $5,635 | -51.88% | |
| 2025-01-15 | Sale | Lunger John | Chief Patient Supply Officer | 9,803 0.0036% | $0.57 | $5,635 | -51.88% | |
| 2025-01-15 | Sale | Bertrand William C JR | Chief Operating Officer | 9,803 0.0036% | $0.57 | $5,635 | -51.88% | |
| 2025-01-13 | Sale | Rawcliffe Adrian | Chief Executive Officer | 30,473 0.0118% | $0.59 | $17,915 | -50.66% | |
| 2025-01-13 | Sale | Norry Elliot | Chief Medical Officer | 12,392 0.0048% | $0.59 | $7,285 | -50.66% | |
| 2025-01-13 | Sale | Lunger John | Chief Patient Supply Officer | 9,739 0.0038% | $0.59 | $5,726 | -50.66% | |
| 2025-01-13 | Sale | Bertrand William C JR | Chief Operating Officer | 9,739 0.0038% | $0.59 | $5,726 | -50.66% | |
| 2024-06-18 | Sale | Piccina Cintia | Chief Commercial Officer | 24,531 0.0086% | $0.93 | $22,814 | -29.55% | |
| 2024-01-17 | Sale | Rawcliffe Adrian | Chief Executive Officer | 30,080 0.0124% | $0.67 | $20,244 | +43.43% | |
| 2024-01-17 | Sale | Norry Elliot | Chief Medical Officer | 18,276 0.0075% | $0.67 | $12,300 | +43.43% | |
| 2024-01-17 | Sale | Lunger John | Chief Patient Supply Officer | 18,114 0.0075% | $0.67 | $12,191 | +43.43% | |
| 2024-01-17 | Sale | Bertrand William C JR | Chief Operating Officer | 18,908 0.0078% | $0.67 | $12,725 | +43.43% | |
| 2024-01-16 | Sale | Rawcliffe Adrian | Chief Executive Officer | 9,304 0.0046% | $0.79 | $7,350 | +46.48% | |
| 2024-01-16 | Sale | Lunger John | Chief Patient Supply Officer | 4,681 0.0023% | $0.79 | $3,698 | +46.48% |
| Rawcliffe Adrian | Chief Executive Officer | 44327 0.0172% | $11,347.71 | 0 | 30 | |
| Piccina Cintia | Chief Commercial Officer | 18421 0.0071% | $4,715.78 | 0 | 4 | |
| Bertrand William C JR | Chief Operating Officer | 7510 0.0029% | $1,922.56 | 1 | 21 | +23.78% |
| Lunger John | Chief Patient Supply Officer | 7510 0.0029% | $1,922.56 | 0 | 26 | |
| Norry Elliot | Chief Medical Officer | 7510 0.0029% | $1,922.56 | 0 | 19 | |
| BARRIS PETER J | 10 percent owner | 82978668 32.1811% | $21.24M | 7 | 0 | <0.0001% |
| BARRETT M JAMES | 10 percent owner | 82978668 32.1811% | $21.24M | 7 | 0 | <0.0001% |
| KERINS PATRICK J | 10 percent owner | 82978668 32.1811% | $21.24M | 7 | 0 | <0.0001% |
| Viswanathan Ravi | 10 percent owner | 82978668 32.1811% | $21.24M | 7 | 0 | <0.0001% |
| New Enterprise Associates 14, L.P. | 10 percent owner | 82978668 32.1811% | $21.24M | 7 | 0 | <0.0001% |
| MOTT DAVID M | 19500000 7.5626% | $4.99M | 8 | 0 | <0.0001% | |
| SANDELL SCOTT D | 10 percent owner | 19500000 7.5626% | $4.99M | 8 | 0 | <0.0001% |
| BASKETT FOREST | 10 percent owner | 19500000 7.5626% | $4.99M | 8 | 0 | <0.0001% |
| Sonsini Peter W. | 10 percent owner | 19500000 7.5626% | $4.99M | 8 | 0 | <0.0001% |
| Florence Anthony A. Jr. | 10 percent owner | 19500000 7.5626% | $4.99M | 8 | 0 | <0.0001% |
| Behbahani Ali | director | 19500000 7.5626% | $4.99M | 2 | 0 | <0.0001% |
| ORBIMED ADVISORS LLC | director | 4901310 1.9008% | $1.25M | 4 | 7 | <0.0001% |
| Thompson Peter A. | director | 4901310 1.9008% | $1.25M | 4 | 7 | <0.0001% |
| Sigal Charles Elliott | director | 314100 0.1218% | $80,409.60 | 4 | 0 | <0.0001% |
| Wood Gavin | Chief Financial Officer | 96000 0.0372% | $24,576.00 | 3 | 0 | <0.0001% |
| Menzel Garry E | director | 75056 0.0291% | $19,214.34 | 0 | 1 | |
| Amado Rafael | President, R&D | 17237 0.0067% | $4,412.67 | 0 | 2 | |
| Alleva Lawrence M | director | 12600 0.0049% | $3,225.60 | 3 | 0 | <0.0001% |
| Binder-Scholl Gwendolyn Knowlton | Chief Technology Officer | 2487 0.001% | $636.67 | 0 | 3 | |
| Noble James | director | 0 0% | $0 | 0 | 2 | |
| TAYTON-MARTIN HELEN KATRINA | Chief Business Officer | 0 0% | $0 | 0 | 2 |
Adaptimmune Therapeutics plc (ADAP) | $992,222,850 | 90 | -12.52% | $66.01M |
$4,898,715 | 46 | 40.75% | $71.52M | |
$332,528,129 | 45 | 28.82% | $70.33M | |
$22,288,598 | 37 | 25.99% | $61.39M | |
$2,239,226 | 28 | 3.41% | $61.84M | |
$1,098,254 | 23 | 1.52% | $66.63M | |
$160,539,875 | 21 | -6.57% | $60.48M | |
$1,602,584 | 20 | 15.26% | $62.29M | |
$1,044,754 | 13 | -23.07% | $55.84M | |
$17,567,343 | 12 | 34.87% | $70.62M | |
$3,871,238 | 10 | -30.38% | $59.11M | |
$91,549,696 | 8 | -6.55% | $69.13M | |
$17,872,846 | 6 | -27.97% | $66.11M | |
$106,599,960 | 6 | -7.63% | $57.15M | |
$20,729,984 | 5 | 51.71% | $67.05M | |
$4,745,999 | 5 | -4.91% | $68.68M | |
$105,079 | 4 | -41.57% | $63.68M | |
$18,186,879 | 4 | 49.41% | $59.46M | |
$19,175,155 | 2 | 40.00% | $67.5M |
| Increased Positions | 27 | +26.73% | 14M | +11.13% |
| Decreased Positions | 37 | -36.63% | 22M | -17.87% |
| New Positions | 10 | New | 244,441 | New |
| Sold Out Positions | 21 | Sold Out | 19M | Sold Out |
| Total Postitions | 91 | -9.9% | 116M | -6.74% |
| Ecor1 Capital, Llc | $7,838.00 | 1.73% | 27.4M | 0 | 0% | 2024-12-31 |
| Long Focus Capital Management, Llc | $5,861.00 | 1.29% | 20.49M | +7M | +54.09% | 2024-12-31 |
| Nea Management Company, Llc | $4,885.00 | 1.08% | 17.08M | 0 | 0% | 2024-12-31 |
| Two Seas Capital Lp | $4,243.00 | 0.94% | 14.84M | +15M | New | 2024-12-31 |
| Baillie Gifford & Co | $3,380.00 | 0.75% | 11.82M | -5M | -29.55% | 2024-12-31 |
| Mpm Asset Management Llc | $1,589.00 | 0.35% | 5.56M | 0 | 0% | 2024-12-31 |
| Mpm Bioimpact Llc | $1,457.00 | 0.32% | 5.1M | 0 | 0% | 2024-12-31 |
| Pfm Health Sciences, Lp | $1,393.00 | 0.31% | 4.87M | -5M | -51.28% | 2024-12-31 |
| Bank Of America Corp /De/ | $819.00 | 0.18% | 2.86M | -2M | -38.49% | 2024-12-31 |
| Renaissance Technologies Llc | $723.00 | 0.16% | 2.53M | +869,949 | +52.52% | 2024-12-31 |